Dr Pan speaks with ecancer at EHA 23 about a novel CD22 CAR-T cell for paediatric B-ALL.

She outlines the remission rates and safety associated with the treatment.

For more on these results, watch her presentation of data at a press session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.